Myelodysplastic Syndromes: Treatment Updates and Emerging Data
The management of myelodysplastic syndromes (MDS) is complicated by the generally advanced age of the patients. The major clinical problems are morbidities caused by cytopenias and the potential for MDS to progress to acute myeloid leukemia.
Category
  • Myelodysplastic Syndromes
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 2.25 AAPA Category 1 CME credit
  • 2.25 ACPE contact hours
  • 2.25 AMA PRA Category 1 Credit™
  • 2.25 ANCC contact hours
  • 2.25 Participation
Cost $0.00
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia
As additional, more effective, and novel therapies are added to the repertoire of cancer therapy, there are increasing numbers of cancer survivors, and these survivors are living for longer periods of time from diagnosis.
Category
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?
Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL).
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL).
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment
The prognostic significance of molecular and cytogenetic variables vary depending on the treatment regimens and clinical outcomes being evaluated.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
Given the high cure rate of classic Hodgkin lymphoma, clinical trials strive to reduce potential long-term toxicities of treatment.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
NCCN Guidelines® Insights - Survivorship, Version 2.2024
These NCCN Guidelines Insights summarize the panel’s current recommendations regarding sexual health and fertility.
Category
  • Survivorship
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Unraveling Cancer Pain Dynamics
This adaptive learning program is designed for healthcare professionals involved in cancer pain management. Tailored to your existing knowledge, it allows you to "test out" of topics you already master. In this fully interactive course, clinicians will explore the safe and effective use of opioid analgesics, optimize non-opioid analgesics and adjuvant medications, and learn to integrate non-pharmacological approaches into comprehensive cancer pain management. Key topics include opioid safety, pain management strategies, non-opioid therapies, and holistic approaches to patient care.
Category
Format
  • Enduring Activity
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Cost $0.00
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Neoadjuvant Treatment Options in Locally Advanced and Metastatic Rectal Cancer with Deficient Mismatch Repair
Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, toxicity management, and appropriate supportive care recommendations throughout a patient’s treatment course.
Category
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00

Pages